Personalized DC Vaccines in Non Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Phase Ib clinical trial using autologous dendritric cell (DC) vaccine loaded with
personalized peptides (PEP) given in combination with low-dose cyclophosphamide, as standard
of care (SOC) therapy in patients with advanced or recurrent metastatic NSCLC.